PHAR - Total Utang marang Modal Pharming Corp
The debt-to-equity dynamics of Pharming Group N.V. (PHAR) demonstrate financial stability, where the value of 0.40 describes the current leverage level. A monopoly on a unique drug for rare pathologies allows the company to exercise pricing power. Despite geopolitical risks in supply chains, stable demand for the core medication ensures a consistent cash generator.
%20-%20Rasio%20Kabeh%20Utang%20marang%20Dana%20Pribadi&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_PHAR_-_Pharming-Group-N.V._-_All-Debt-to-Shareholders-Equity-Ratio "PHAR (Pharming Group N.V.) riwayat Total Utang marang Modal saka 04.07.2022 nganti 29.10.2026 | 👁️GURU.Markets👁️")
Rincian analitis perusahaan Pharming Group N.V.
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Pharming Group N.V.|PHAR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Pharming Group N.V.|PHAR - Gunggung utang perusahaan|Utang marang nilai buku Pharming Group|PHAR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pharming Group|Likuiditas cepet pharming.com
- informasi bathi lan kelipatan valuasi:
Analisis dhasar perusahaan:Pharming Group
Pharming Group N.V. specializes in biopharmaceuticals, delegating the production of protein-based drugs to external CMO partners. This metric compares total liabilities to equity to assess the business's leverage. This allows the investor to determine the company's financial stability given its high operational dependence on outsourcing. A decrease in this ratio confirms the effectiveness of risk management. By analyzing changes in the total debt-to-equity level, one can evaluate the alignment of management's strategy with reality.
Analisis pesaing Pharming Group N.V.
Utang marang Ekuitas argenx|BioNTech Inc. - Utang Agregat marang Ekuitas|Total Utang marang Modal ABVX|ADMA (ADMA Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTGX (Protagonist Therapeutics)|Total Utang marang Modal immunovant.com IMVT|KNSA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal biocryst.com|Rasio Total Utang marang Ekuitas VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PHVS (Pharvaris Corp)|Koefisien Total Utang marang Modal AbCellera (ABCL)|TRML - Utang marang Ekuitas|precigen.com (PGEN) - Rasio Total Utang marang Ekuitas|Nektar Therapeutics Inc. (NKTR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Upstream Bio, Inc.|Rasio Total Utang marang Ekuitas ZBIO|Total Utang marang Modal Immunome Bio|Utang marang Ekuitas Gossamer Bio, Inc. (GOSS)|kalvista.com - Rasio Utang marang Ekuitas|Total Utang marang Modal SEPN (Septerna)|Pieris Pharma (PVLA) - Utang marang Modal|SVRA - Utang marang Ekuitas|Utang Agregat marang Ekuitas RIGL|ANAB: Total Utang marang Modal|astriatx.com - Rasio Kabeh Utang marang Dana Pribadi|ENGN (enGene) - Total Utang marang Modal|Total Utang marang Modal RAPT Therapeutics Inc.|Utang marang Ekuitas Aerovate Therapeutics Inc (JBIO)|ACRS (Aclaris Therapeutics, Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Kyverna Therapeutics KYTX|TLSA - Rasio Total Utang marang Ekuitas|Cabaletta Bio - Total Utang marang Modal|Koefisien Total Utang marang Modal Ventyx Biosciences Inc. VTYX|Theratechnologies Inc (THTX) - Utang marang Ekuitas|Rasio Utang marang Ekuitas AVTX|ELDN (Eledon Pharmaceuticals) - Total Utang marang Modal|AGEN - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas CLYM (Climb Bio)|ZURA (Zura Bio Ltd) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ATYR (aTyr)|Rasio Utang marang Modal Adagene Inc|IMA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi STTK (Shattuck Labs, Inc.)|equilliumbio.com (EQ) - Utang marang Ekuitas|Utang marang Modal Connect Biopharma Holdings Limited (CNTB)|Rasio Total Utang marang Ekuitas IMUX|Total Utang marang Modal Atara Biotherapeutics Inc|Utang marang Ekuitas InflaRx N.V. (IFRX)|XFOR: Utang Agregat marang Ekuitas|Adicet Bio, Inc. - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CELU|INMB - Utang marang Ekuitas|BRNS (Barinthus Biotherapeutics Corp) - Rasio Utang marang Ekuitas|KZR (Kezar Life Sciences) - Rasio Total Utang marang Ekuitas|SABS - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas AKTX|Utang marang Ekuitas ENLV|Rasio Total Utang marang Ekuitas QTTB (Q32 Bio Inc.)|Koefisien Total Utang marang Modal GeoVax Corp|Utang marang Ekuitas Edesa Biotech, Inc. EDSA|IBIO (ibioinc.com) - Utang Agregat marang Ekuitas|Carisma Tx - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi XTLB (XTL Biopharmaceuticals Ltd)|BOLT: Total Utang marang Modal|HCW Biologics (HCWB) - Total Utang marang Modal|Utang marang Ekuitas Aptevo Therapeutics, Inc.|AIM: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Aditxt (ADTX)|GRI: Utang Agregat marang Ekuitas|Total Utang marang Modal XRTX (XORTX)|Rasio Kabeh Utang marang Dana Pribadi HIND|Revelation Biosciences - Total Utang marang Modal|INDP - Total Utang marang Modal|Scinai Immunotherapeutics Ltd. (SCNI) - Utang marang Ekuitas|CalciMedica - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Affimed NV|Rasio Total Utang marang Ekuitas Allakos Therapeutics (ALLK)|Total Utang marang Modal HOOK|Total Utang marang Modal igmbio.com (IGMS)|iTeos Therapeutics, Inc. - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi OCEA|TC BioPharm (Holdings) PLC - Total Utang marang Modal|Koefisien Total Utang marang Modal Third Harmonic Bio Inc THRD